Insumos Agroquimicos S.A. Overview
InsuAgro is a mid-sized, asset-light Argentine marketer and distributor of crop-protection and crop-nutrition products, founded in 2002 and controlled since April 2021 by Bioceres Crop Solutions Corp. It sells a broad, largely off-patent portfolio — herbicides, insecticides, fungicides, seed treatments, adjuvants, water correctors, growth regulators, plant-nutrition and biostimulation products — exclusively through agricultural retailers, organised into eleven sales zones each led by a senior agronomist. Its addressable crops span soybean, corn, wheat, sunflower, potato, beans, peanut, pastures and tobacco. Revenue reached ARS 41.1 billion in FY2026, but the business has slipped into operating losses for two consecutive years, carries net debt of ARS 25.4 billion against equity of ARS 6.1 billion, and received a going-concern qualification on its FY2025 accounts. Its strategic future is tightly bound to the restructuring of the Bioceres group, whose founding holding company was declared bankrupt in March 2026.
What the company does. InsuAgro sources formulated agrochemicals and nutrition products from manufacturers and toll formulators — historically disclosed principal suppliers include FMC Química, Cheminova (now part of FMC), Borches y Cía and Rainbow Agrosciences (MAV, Fideicomiso Financiero Insuagro VI presentation, 2020) — and markets them under its own brands to Argentine farm-input retailers. Some descriptions of the business refer to "production" as well as distribution (Fintel; TradingView); the balance sheet shows modest property, plant and equipment (ARS 2,291M at FY2026, including land ARS 663M, buildings ARS 1,677M and machinery ARS 1,201M at gross values per S&P), which is consistent with warehousing and possibly light formulation or repackaging rather than active-ingredient synthesis. The company's own characterisation, used in its securitisation marketing materials, is that of a "comercializadora de insumos agropecuarios" (agricultural inputs trading company) with presence in all of Argentina's farming regions (MAV, Insuagro XII presentation).
Company's own description (paraphrased from its trust-programme presentations and website). InsuAgro describes itself as a company created in 2002 that markets agricultural inputs nationwide, whose wide product range gives it access to the soybean, corn, wheat, sunflower, potato, bean, peanut, pasture and tobacco markets; it sells exclusively to retail outlets through eleven sales zones, each overseen by an experienced agronomist acting as zonal supervisor; it highlights a complete product line, very low geographic and customer concentration, a professional sales force that builds customer loyalty, and agility derived from limited investment in fixed assets. Since 2021 it presents itself as part of the Argentine Bioceres group (MAV, Insuagro XII presentation; company website).
Business model and revenue model. Revenue is essentially 100% product sales (no material service, subscription or licensing revenue is disclosed). S&P's segment data splits revenue into Crop Protection (75.8% of FY2026 revenue) and Crop Nutrition (24.2%). The model is a classic "distributor-formulator" spread business: buy generic molecules on supplier credit (often USD-denominated), brand and position them, and sell on seasonal credit terms to retailers, financing the receivables gap through bank debt, negotiable obligations, and — distinctively — public-offering financial trusts that securitise trade receivables (Fideicomisos Financieros "Insuagro" series). InsuAgro acts as trustor (fiduciante), servicer and collection agent for these trusts, retains the participation certificates, and has agreed to replace defaulted receivables (BIOX 20-F FY2021, Note on Insuagro acquisition).
Value-chain position. Downstream of global and Chinese/Indian active-ingredient manufacturers and formulators, upstream of retailers ("agronomías", cooperatives, distributors) who in turn sell to farmers. InsuAgro does not appear to own molecule IP; its value-add lies in registration management (SENASA product registrations), branding, agronomic advice and credit provision.
Customer types. Agricultural input retailers and distributors only (no direct farmer sales are disclosed). Customer concentration is described as very low (MAV presentations); no customer above 10% of revenue is disclosed.
End-markets. Argentine extensive crops (soy, corn, wheat, sunflower), regional/specialty crops (potato, beans, peanut, tobacco) and pastures. Geographic coverage includes the northwest, northeast and central farming regions (Fintel profile) — effectively the whole Argentine grain belt.
Independent characterisation. InsuAgro is a sub-scale generic agrochemical brand-owner whose economics are driven less by product innovation than by working-capital management in a high-inflation, devaluation-prone, credit-intensive market. In FY2022 it earned an 11% EBIT margin; by FY2025–FY2026 the same gross margin structure (22–23%) no longer covered a sharply higher SG&A base (SG&A ≈ 24% of revenue), and financial costs, FX losses and bad-debt provisions (ARS 1,069M in FY2026) pushed it into net losses. Its strategic value inside the Bioceres group was as a distribution channel and as an additional crop-protection catalogue alongside sister company Rizobacter; that rationale is now subordinate to group liquidity.
Strategy
Stated strategy (themes, paraphrased). No investor-day material or strategic plan for InsuAgro is publicly available. Its recurring self-description emphasises: (1) a broad, complete product line; (2) low customer and geographic concentration; (3) a professional agronomist-led sales force that builds retailer loyalty; (4) asset-light agility to adapt to market and macro changes (MAV presentations); and, since 2021, (5) belonging to the Bioceres group, with "the same values" and "more strength and projects" (company website).
Group-level strategic context (Bioceres Crop Solutions). BIOX's stated rationale in 2021 was the reorganisation of its crop-protection business segment (BIOX 20-F FY2021). In FY2025–FY2026, BIOX announced a transition in its seed business model and the elimination of low-margin, working-capital-intensive sales, which reduced Q1 FY2026 revenue 17% to US$77.5M while gross margin rose from 40% to 47% (Safras, reporting BIOX Q1 FY2026). InsuAgro's FY2026 inventory and payables reduction is directionally consistent with this group-wide working-capital discipline — an analyst inference.
Announced initiatives in the last 24 months (InsuAgro-specific):
Medium-term targets / guidance: None publicly disclosed.
Products & Services
InsuAgro publishes a product catalogue on its website (Productos section) and product manuals ("Manuales InsuAgro"), but the individual product pages could not be retrieved in this research. The table below lists every product name verifiable from public sources; technical specifications, launch years and pricing are not publicly disclosed in the sources reviewed. Active-ingredient descriptions marked "(inferred from name)" are analyst inferences from the brand name and should be verified against SENASA registrations.
Crop Protection
| Product | Category | Description / likely active ingredient | Target customer | Launch / version year | Pricing model |
|---|---|---|---|---|---|
| Affinity | Herbicide (category as listed by aggregators; inferred) | — | Retailers serving extensive-crop growers | — | — |
| Danken Max | — | — | Retailers | — | — |
| Dicamba Block | Herbicide | Dicamba-based broadleaf herbicide (inferred from name); used in fallow and pre-plant weed control | Retailers / extensive crops | — | — |
| Florane | — | — | Retailers | — | — |
| Metolacloro | Herbicide | S-metolachlor/metolachlor pre-emergent grass herbicide (inferred from name) for soy, corn, sunflower, peanut | Retailers | — | — |
| Super Onecide | Herbicide | Graminicide (inferred: "Onecide" is a known fluazifop-p-butyl brand family); post-emergent grass control in broadleaf crops | Retailers | — | — |
| Imiseed Flow | Seed treatment | Imidacloprid-based flowable seed treatment (inferred from name) | Retailers / seed treaters | — | — |
| Ishioil | Adjuvant | Oil-based adjuvant (inferred from name) | Retailers | — | — |
| Paraquat Stockton | Herbicide | Paraquat desiccant/burndown herbicide (inferred from name) | Retailers | — | — |
| Salix | — | — | Retailers | — | — |
| Lamda | Insecticide | Lambda-cyhalothrin pyrethroid insecticide (inferred from name) | Retailers | — | — |
| Fungicides (range) | Fungicide | Products not individually named in sources reviewed | Retailers | — | — |
| Growth regulator | Plant growth regulator | Named in MAV presentations as a category; product not named | Retailers | — | — |
| Water correctors | Spray-water conditioners | Named as a category in MAV presentations | Retailers | — | — |
Crop Nutrition / Biostimulation
| Product line | Category | Description | Target customer | Launch year | Pricing |
|---|---|---|---|---|---|
| Plant nutrition line | Foliar/soil nutrition | Listed by S&P business description; product names not disclosed | Retailers | — | — |
| Plant biostimulation | Biostimulants | Listed by S&P business description | Retailers | — | — |
| Environmental formulations | Lower-impact formulations | Listed by S&P business description; the website also has a "Medio Ambiente" section | Retailers | — | — |
| Inoculants | Biologicals | TradingView lists inoculants among products | Retailers | — | — |
Services
Agronomic advisory: via zonal agronomist supervisors (eleven zones) — bundled with product sales, not separately priced (MAV presentations).
"Nuevas Tecnologías": a website section indicates new-technology content, likely linked to Bioceres-group technologies; specifics not publicly disclosed.
Commentary. The portfolio is characteristic of a generic "me-too" player: widely available molecules (dicamba, paraquat, metolachlor, imidacloprid, lambda-cyhalothrin, fluazifop) where differentiation rests on formulation quality, availability, credit and service. Paraquat's regulatory status is a latent portfolio risk (banned in many jurisdictions; Argentine regulatory status should be monitored).
Financial Narrative
Source for all figures unless noted: S&P Global Market Intelligence via StockAnalysis.com (income statement, balance sheet, cash-flow statement pages; last updated 14 Sep 2026). ARS millions; nominal as originally reported per fiscal year; fiscal years end 30 June.
Income statement
Dividends per share: S&P records ARS 7.195 per share attributable to FY2024 only. Conflict: TradingView states INAG has never paid dividends, while the S&P cash-flow series shows common dividends paid in FY2022–FY2025 (see 6.4). The discrepancy may reflect distributions to non-controlling holders of consolidated trusts being classified as dividends by the aggregator, or simply an aggregator error; it could not be resolved from primary filings.
TTM check: for the twelve months to 31 March 2026, StockAnalysis showed revenue of ARS 43,820M (+0.3%) and net income of ARS −1,850M (snapshot of 22 Jul 2026).
Margins (%)
SG&A-to-revenue is analyst-computed; others from S&P: Revenue CAGR FY2022–FY2026: 46.4% per year nominal (analyst-computed: (41,059 / 8,940)^(1/4) − 1).
Commentary — income statement. Three inflections stand out. (1) FY2022 was the high-water mark for profitability: 27% gross margin and 11% EBIT margin, the year that triggered the US$0.965/share earn-out to sellers under Bioceres' acquisition agreement (BIOX 20-F FY2025). (2) FY2024's nominal explosion (+244%) coincided with the December 2023 peso devaluation; it inflated revenue but also produced ARS 4,403M of FX losses, offset by ARS 2,145M of interest/investment income and ARS 2,237M of other non-operating gains, leaving a near-zero pre-tax result. (3) FY2025–FY2026 structural deterioration: gross margin held at 22–23%, but SG&A rose to ~24% of revenue (the FY2025 SG&A jump of 60% nominal against revenue growth of 29% indicates either cost inflation running ahead of pricing, higher freight/logistics, or — likely significant — bad-debt provisions, which rose from ARS 317M in FY2024 to ARS 520M in FY2025 and ARS 1,069M in FY2026 per the cash-flow add-backs). Operating income turned negative and financial charges (interest, FX, other) produced pre-tax losses of ARS 3.5bn and 2.5bn. FY2026 also benefited from ARS 791M of "other unusual items" (nature not disclosed), without which the pre-tax loss would have been ~ARS 3.3bn.
Balance sheet
Goodwill is zero at the InsuAgro level (goodwill from the 2021 acquisition sits in Bioceres' consolidated accounts). Lease totals are analyst-summed from current and long-term lease lines.
Source conflict: FinancialFilings.com reports FY2025 total assets of ARS 60,933.35M and total equity of ARS 7,049.64M per the annual report filed 9 Sep 2025, versus S&P's ARS 60,921M and ARS 7,050M — immaterial differences, likely rounding/classification.
Commentary — balance sheet. The balance sheet is dominated by trade receivables (64% of total assets in FY2026) funded by supplier credit and debt. Two FY2026 movements are striking: accounts payable fell by ARS 15.0bn (from 37.6bn to 22.5bn) while long-term debt rose by ARS 16.8bn (from 6.2bn to 23.0bn) and short-term debt fell by ARS 4.8bn. The most plausible reading — an analyst inference not confirmed by primary disclosure — is that overdue supplier balances and short-term financing were refinanced or converted into long-dated financial debt (possibly with related parties or principal suppliers), which explains both the jump in working capital to ARS 23.9bn and the improvement in the current ratio. Equity has been eroded by ARS 1.2bn across FY2025–FY2026 in nominal terms (a much larger real erosion), and leverage (debt/equity) has risen to 4.5x.
Cash flow
Capex is shown blank for FY2022 because S&P reports no figure; FY2026 dividends shown as 0 because none were reported; buybacks: none disclosed in any year.
Source conflict: FinancialFilings.com cites FY2025 cash from operations of ARS −1,159.15M per the annual report, versus ARS −656.97M in the S&P series. The difference (~ARS 502M) likely reflects classification of interest or securitisation flows; the primary figure should be preferred once retrieved.
Commentary — cash flow. For four consecutive years (FY2022–FY2025) InsuAgro consumed operating cash to fund working-capital growth, financed by net debt issuance of ARS 13.8bn cumulatively. FY2026 is the first year of positive operating cash flow (ARS 4.9bn), driven primarily by an inventory release of ARS 3.9bn rather than by profitability; the cash was used to repay ARS 4.1bn of net debt. Capex is negligible (under 0.2% of revenue), confirming the asset-light model. Cash interest paid tripled in FY2026 to ARS 1.3bn even as the income-statement interest expense fell, suggesting settlement of accrued interest during refinancing.
Ratios (analyst-computed from year-end balances unless noted)
ROIC = EBIT × (1 − 35%) / (equity + total debt − cash & short-term investments); 35% is Argentina's top statutory corporate rate used as a notional assumption. Working-capital day counts use year-end balances against annual flows; because June year-end balances are restated to closing-date currency while flows accumulate through the year, day counts are upward-biased in high-inflation years and should be read directionally only.
Commentary — ratios. Returns collapsed from an exceptional FY2022 (ROE 36%, ROIC ~39%) to negative territory. Interest coverage has been at or below 1x since FY2023, meaning the business has not covered its financing cost from operations for three years. The FY2026 cash-conversion cycle lengthened to ~183 days because payables days fell sharply (supplier balances moved to financial debt), a shift that transfers liquidity pressure from suppliers to lenders. The improvement in the current ratio to 1.85x is a product of term-out rather than of organic de-leveraging.
Unlock Company Financials
Unlock this company profile to view its financial data.
View Subscription PlansFinancial Detail
Segment Overview
| Segment | Contents | Representative products (where identifiable) |
|---|---|---|
Crop Protection | Herbicides, insecticides, fungicides, seed treatments ("curasemillas"), adjuvants/synergists, water correctors, growth regulators | Affinity, Danken Max, Dicamba Block, Florane, Metolacloro, Super Onecide, Imiseed Flow, Ishioil, Paraquat Stockton, Salix, Lamda (Fintel) |
Crop Nutrition | Plant-nutrition line, plant biostimulation, environmental formulations | Product names not publicly disclosed in sources reviewed |
Crop Protection | 31,137 | 0 |
Crop Nutrition | 9,923 | 0 |
Revenue by Segment
| Segment | FY2023 | FY2024 | FY2025 | FY2026 |
|---|---|---|---|---|
Crop Protection revenue (ARS Mn) | 7,883 | 26,202 | 34,620 | 31,137 |
Crop Nutrition revenue (ARS Mn) | 1,884 | 7,398 | 8,688 | 9,923 |
Total revenue (ARS Mn) | 9,767 | 33,601 | 43,309 | 41,059 |
Unlock Company Financials
Unlock this company profile to view its financial data.
View Subscription PlansSegment Margins & Growth (%)
| Segment | FY2024 | FY2025 | FY2026 |
|---|---|---|---|
Crop Protection YoY growth (%) | 232.4 | 32.1 | -10.1 |
Crop Nutrition YoY growth (%) | 292.7 | 17.4 | 14.2 |
Total YoY growth (%) | 244.0 | 28.9 | -5.2 |
Revenue by Segment (%)
| Segment | FY2023 | FY2024 | FY2025 | FY2026 |
|---|---|---|---|---|
Crop Protection share of revenue (%) | 80.7 | 78.0 | 79.9 | 75.8 |
Crop Nutrition share of revenue (%) | 19.3 | 22.0 | 20.1 | 24.2 |
Unlock Company Financials
Unlock this company profile to view its financial data.
View Subscription PlansIncome Statement and Margin Analysis (%)
| Metric | FY2022 | FY2023 | FY2024 | FY2025 | FY2026 |
|---|---|---|---|---|---|
Revenue (ARS Mn) | 8,940 | 9,767 | 33,601 | 43,309 | 41,059 |
Revenue growth YoY (%) | 100.81 | 9.24 | 244.03 | 28.89 | -5.19 |
Cost of revenue (ARS Mn) | 6,495 | 7,578 | 25,344 | 33,778 | 31,476 |
Gross profit (ARS Mn) | 2,446 | 2,189 | 8,257 | 9,531 | 9,584 |
SG&A (ARS Mn) | 1,482 | 1,507 | 6,160 | 9,885 | 9,901 |
Operating income / EBIT (ARS Mn) | 987.48 | 681.05 | 2,073 | -340.2 | -336.63 |
D&A used in EBITDA (ARS Mn) | 34.46 | 39.5 | 147.66 | 232.34 | 238.7 |
EBITDA (ARS Mn) | 1,022 | 720.55 | 2,220 | -107.86 | -97.93 |
Interest expense (ARS Mn) | 747.18 | 716.15 | 1,982 | 1,705 | 1,269 |
Interest and investment income (ARS Mn) | 419.57 | 717.58 | 2,145 | 533.79 | 323.39 |
Currency exchange gain or loss (ARS Mn) | -128.52 | -311.52 | -4,403 | -1,120 | -783.93 |
Other non-operating income or expense (ARS Mn) | 32.69 | -49.16 | 2,237 | -757.61 | -1,244 |
Pre-tax income (ARS Mn) | 565.73 | 283.58 | -22.91 | -3,525 | -2,485 |
Income tax expense (ARS Mn) | 248.99 | 296.51 | -253.24 | -1,279 | -183.51 |
Net income (ARS Mn) | 316.74 | -12.93 | 230.33 | -2,246 | -2,301 |
EPS basic (ARS) | 14.40 | -0.59 | 10.47 | -102.07 | -104.60 |
EPS diluted (ARS) | 14.40 | -0.59 | 10.47 | -102.07 | -104.60 |
Weighted shares basic (M) | 22 | 22 | 22 | 22 | 22 |
Advertising expense (ARS Mn) | — | 72.52 | 480.56 | 332.98 | 265.43 |
Unlock Company Financials
Unlock this company profile to view its financial data.
View Subscription PlansMargin Analysis (%)
| Metric | FY2022 | FY2023 | FY2024 | FY2025 | FY2026 |
|---|---|---|---|---|---|
Gross margin (%) | 27.36 | 22.41 | 24.57 | 22.01 | 23.34 |
SG&A to revenue (%) | 16.58 | 15.43 | 18.33 | 22.82 | 24.11 |
Operating margin (%) | 11.04 | 6.97 | 6.17 | -0.79 | -0.82 |
EBITDA margin (%) | 11.43 | 7.38 | 6.61 | -0.25 | -0.24 |
Pre-tax margin (%) | 6.33 | 2.90 | -0.07 | -8.14 | -6.05 |
Net margin (%) | 3.54 | -0.13 | 0.69 | -5.18 | -5.60 |
Balance Sheet and Per-Share Data
| Metric | FY2022 | FY2023 | FY2024 | FY2025 | FY2026 |
|---|---|---|---|---|---|
Total assets (ARS Mn) | 5,288 | 12,497 | 53,748 | 60,921 | 57,212 |
Cash and equivalents (ARS Mn) | 28.43 | 25.55 | 158.44 | 1,244 | 1,908 |
Short-term investments (ARS Mn) | 418.33 | 650.83 | 1,128 | 17.16 | 20.17 |
Cash and short-term investments (ARS Mn) | 446.77 | 676.39 | 1,286 | 1,261 | 1,928 |
Trade accounts receivable (ARS Mn) | 2,663 | 6,683 | 34,892 | 39,616 | 36,738 |
Total receivables (ARS Mn) | 2,787 | 7,265 | 36,901 | 41,328 | 39,131 |
Inventory (ARS Mn) | 1,742 | 3,900 | 12,241 | 13,679 | 10,114 |
Total current assets (ARS Mn) | 5,002 | 11,878 | 50,429 | 56,766 | 52,076 |
Net PP&E (ARS Mn) | 228.89 | 452.67 | 1,520 | 1,889 | 2,291 |
Intangible assets (ARS Mn) | 35.15 | 74.47 | 375.28 | 599.75 | 669.17 |
Goodwill (ARS Mn) | 0 | 0 | 0 | 0 | 0 |
Accounts payable (ARS Mn) | 2,912 | 6,115 | 30,615 | 37,578 | 22,531 |
Short-term debt (ARS Mn) | 841.73 | 2,851 | 7,491 | 9,032 | 4,220 |
Long-term debt (ARS Mn) | 379.55 | 778.37 | 6,733 | 6,195 | 22,995 |
Lease liabilities total (ARS Mn) | 0 | 4.2 | 31.33 | 118.18 | 78.77 |
Total debt incl. leases (ARS Mn) | 1,221 | 3,634 | 14,255 | 15,346 | 27,294 |
Net debt (ARS Mn) | 774.51 | 2,957 | 12,968 | 14,085 | 25,366 |
Total current liabilities (ARS Mn) | 3,913 | 9,440 | 39,523 | 47,615 | 28,148 |
Total liabilities (ARS Mn) | 4,409 | 10,537 | 46,511 | 53,871 | 51,152 |
Shareholders' equity (ARS Mn) | 879.6 | 1,959 | 7,237 | 7,050 | 6,060 |
Working capital (ARS Mn) | 1,089 | 2,438 | 10,905 | 9,151 | 23,929 |
Book value per share (ARS) | 39.98 | 89.06 | 328.94 | 320.44 | 275.44 |
Cash Flow and Margin Analysis (%)
| Metric | FY2022 | FY2023 | FY2024 | FY2025 | FY2026 |
|---|---|---|---|---|---|
Operating cash flow (ARS Mn) | -1,228 | -2,780 | -4,860 | -656.97 | 4,866 |
Capital expenditures (ARS Mn) | — | 24.2 | 56.6 | 6.8 | 22.45 |
Purchase of intangibles (ARS Mn) | 8.44 | 9.46 | 140.54 | 174.19 | 52.83 |
Free cash flow (ARS Mn) | -1,228 | -2,805 | -4,916 | -663.76 | 4,843 |
Free cash flow margin (%) | -13.73 | -28.72 | -14.63 | -1.53 | 11.80 |
Change in working capital (ARS Mn) | -2,417 | -3,494 | -7,561 | -1,465 | 3,266 |
Provision and write-off of bad debts (ARS Mn) | 44.08 | 28.59 | 316.64 | 519.9 | 1,069 |
Net debt issued or repaid (ARS Mn) | 1,133 | 3,085 | 7,893 | 1,681 | -4,084 |
Common dividends paid (ARS Mn) | 41.93 | 106.01 | 100.62 | 158.3 | 0 |
Share buybacks (ARS Mn) | 0 | 0 | 0 | 0 | 0 |
Cash interest paid (ARS Mn) | — | 334.25 | 688.62 | 416.04 | 1,302 |
Investing cash flow (ARS Mn) | 147.81 | -456.15 | -3,507 | 517.92 | 886.35 |
Financing cash flow (ARS Mn) | 1,091 | 3,234 | 8,500 | 1,224 | -5,088 |
Returns & Leverage Ratios (%) and Financial Ratios (x)
| Ratio | FY2022 | FY2023 | FY2024 | FY2025 | FY2026 |
|---|---|---|---|---|---|
ROE on year-end equity (%) | 36.0 | -0.7 | 3.2 | -31.9 | -38.0 |
ROA on year-end assets (%) | 6.0 | -0.1 | 0.4 | -3.7 | -4.0 |
ROIC after 35% notional tax (%) | 38.8 | 9.0 | 6.7 | -1.0 | -0.7 |
Current ratio (x) | 1.28 | 1.26 | 1.28 | 1.19 | 1.85 |
Debt to equity (x) | 1.39 | 1.86 | 1.97 | 2.18 | 4.50 |
Net debt to EBITDA (x; blank where EBITDA negative) | 0.76 | 4.10 | 5.84 | — | — |
EBIT interest coverage (x) | 1.32 | 0.95 | 1.05 | -0.20 | -0.27 |
Asset turnover on year-end assets (x) | 1.69 | 0.78 | 0.63 | 0.71 | 0.72 |
Days sales outstanding (days) | 108.7 | 249.7 | 379.0 | 333.9 | 326.6 |
Days inventory outstanding (days) | 97.9 | 187.8 | 176.3 | 147.8 | 117.3 |
Days payables outstanding (days) | 163.6 | 294.5 | 440.9 | 406.1 | 261.3 |
Cash conversion cycle (days) | 43.0 | 143.0 | 114.4 | 75.6 | 182.6 |
Revenue by Region
| Region | FY2023 | FY2024 | FY2025 | FY2026 |
|---|---|---|---|---|
Argentina revenue (ARS Mn) | 9,767 | 33,601 | 43,309 | 41,059 |
Rest of world revenue (ARS Mn) | 0 | 0 | 0 | 0 |
Region Margins & Growth (%)
| Region | FY2024 | FY2025 | FY2026 |
|---|---|---|---|
Argentina revenue growth (%) | 244.0 | 28.9 | -5.2 |
Share Price History
| Date | Price (ARS) | Note | Source |
|---|---|---|---|
12 Sep 2025 | 7,400 | Reported +146.7% move | Fintel |
22 Jan 2026 | 7,000 | 1-year CAGR shown as 152% | iocharts |
24 Apr 2026 | ~5,886 implied | From market cap ARS 129,500M / 22M shares | Fintel (analyst-derived) |
7 Jul 2026 | 700 | Likely erroneous or anomalous print | StockAnalysis |
22 Jul 2026 | 7,000 | 52-week range shown 650–7,000 | StockAnalysis |
1 Sep 2026 | 6,850 | Last verified trade | StockAnalysis |
Valuation Multiples
| Multiple | At ARS 6,850 (mkt cap ~ARS 150,700M) | At ~ARS 700 (mkt cap ~ARS 15,400M per StockAnalysis) |
|---|---|---|
P/E | n/m (loss) | n/m (loss) |
EV/EBITDA | n/m (negative EBITDA) | n/m |
EV/Sales | ~4.29x (EV ~ARS 176,100M) | ~0.99x (EV ~ARS 40,800M) |
P/B | ~24.9x | ~2.5x |
P/FCF | ~31x | ~3.2x (StockAnalysis shows 3.11x) |
Dividends & Capital Returns and Per-Share Data
| Metric | FY2022 | FY2023 | FY2024 | FY2025 | FY2026 |
|---|---|---|---|---|---|
Dividends paid in cash (ARS Mn) | 41.93 | 106.01 | 100.62 | 158.3 | 0 |
Dividend per share recorded (ARS) | — | — | 7.195 | — | — |
Capital Instruments
| Instrument | Agency | Rating | Date |
|---|---|---|---|
Corporate issuer rating (Moody's/S&P/Fitch) | — | Not rated | — |
FF Insuagro VI Class A debt securities | FIX SCR (Fitch affiliate) | AAsf(arg) | 2020 |
FF Insuagro VI Class B | FIX SCR | Asf(arg) | 2020 |
FF Insuagro VI participation certificates | FIX SCR | CCCsf(arg) | 2020 |
FF Insuagro VII Class A | FIX SCR | AAsf(arg) | Dec 2020 |
FF Insuagro VII Class B | FIX SCR | Asf(arg) | Dec 2020 |
FF Insuagro VII participation certificates | FIX SCR | CCsf(arg) | Dec 2020 |
Later trusts (VIII–XII) | FIX SCR | — | 2021–2025 |
Debt Maturity Profile
| Maturity bucket | FY2022 | FY2023 | FY2024 | FY2025 | FY2026 |
|---|---|---|---|---|---|
Short-term debt within 12 months (ARS Mn) | 841.73 | 2,851 | 7,491 | 9,032 | 4,220 |
Long-term debt beyond 12 months (ARS Mn) | 379.55 | 778.37 | 6,733 | 6,195 | 22,995 |
Lease liabilities (ARS Mn) | 0 | 4.2 | 31.33 | 118.18 | 78.77 |
Analyst Conclusions
Management guidance: None publicly disclosed.
Consensus growth expectations: None (no coverage).
Bull case
-
Cash inflection is real: FY2026 operating cash flow of ARS 4.9bn and net debt repayment of ARS 4.1bn show the business can self-fund when it shrinks inventory; with debt termed out (84% long-term), management has runway to restore margins.
-
Margin repair is a cost problem, not a gross-margin problem: gross margin (23.3%) is intact; returning SG&A from ~24% to the ~16–18% of FY2022–FY2024 would restore a mid-single-digit EBIT margin, and normalising bad-debt charges toward FY2024 levels alone would add ~ARS 0.75bn.
-
Strategic optionality: a distressed parent may sell its 61.3% stake; a better-capitalised acquirer could value InsuAgro's retailer network and registrations, and minority holders would be entitled to a mandatory tender offer under Argentine rules.
Bear case
-
Persistent losses and going-concern doubt: two consecutive years of EBIT losses, sub-1x interest coverage since FY2023, and an auditor going-concern flag suggest equity (ARS 6.1bn, falling) may continue to erode.
-
Contagion from the Bioceres collapse: bankruptcy of Bioceres S.A., BIOX's going-concern doubt, Nasdaq deficiency and New York litigation could restrict supplier credit, trust-market access and bank lines for InsuAgro, or force asset sales on unfavourable terms.
-
Commoditised portfolio under deflation: Crop Protection revenue is shrinking (−10.1% nominal FY2026, far worse in real terms) amid generic price pressure, while receivables equal ~6x equity, leaving little buffer if the farm credit cycle turns.
Key catalysts and monitorables (next 12 months)
-
Q1 FY2027 results (quarter to 30 Sep 2026; expected ~November 2026): gross margin, SG&A ratio, bad-debt charges.
-
Whether the auditor's FY2026 report retains the going-concern emphasis.
-
Disclosure of terms behind the FY2026 long-term debt increase (lender, currency, covenants, related-party status).
-
BIOX restructuring outcomes: Nasdaq listing status, New York litigation, any disposal of the InsuAgro stake, and the Bioceres S.A. bankruptcy proceedings in Rosario.
-
New financial-trust issuance under the INSUAGRO programme (a signal of market access).
-
2026/27 Argentine planting season (soybean vs corn area) and weather.
-
Argentine FX regime and inflation path, which drive FX losses and nominal working capital.
-
Regulatory actions on paraquat, glyphosate, dicamba.
Analyst verdict. Insumos Agroquímicos is a small, asset-light Argentine generic agrochemical marketer whose economics have deteriorated sharply since its peak FY2022 profitability. The core franchise — a broad portfolio sold through a diversified network of retailers, supported by agronomist-led zonal coverage and a long record of receivables securitisation — is still intact at the gross-margin line, which has held at 22–23%. The problem lies below gross profit: SG&A has climbed to roughly a quarter of revenue, credit losses have tripled in two years, and financing and FX costs have consumed whatever operating profit remained. The result is two consecutive years of net losses of about ARS 2.2–2.3 billion, an auditor's going-concern emphasis, and leverage of 4.5x debt-to-equity.
FY2026 brought a genuine but low-quality improvement: positive operating cash flow driven by inventory liquidation and a conversion of short-term supplier and bank obligations into long-term debt. This buys time but does not by itself restore profitability, and the terms of the new long-dated liabilities are undisclosed — a critical gap for any credit or equity view.
The overriding variable is the parent. Bioceres Crop Solutions, which owns 61.3%, carries its own going-concern doubt, faces a Nasdaq deficiency notice and noteholder litigation, and sits beneath a founding holding company that a Rosario court declared bankrupt in March 2026. InsuAgro's access to supplier credit, trust markets and bank lines is likely to track the group's credibility.
For equity investors, INAG is effectively uninvestable on fundamentals alone: it has a ~28% float, sporadic trading, contradictory price prints differing tenfold, and no coverage. Its value lies chiefly in event optionality — a stake sale triggering a tender offer. For credit investors, senior trust tranches backed by diversified receivables remain the safer exposure. Overall stance: high risk, speculative; monitor parent restructuring and FY2026 audit opinion before any position.
Principal sources consulted
-
S&P Global Market Intelligence data via StockAnalysis.com — INAG income statement, balance sheet, cash flow, KPIs, company profile (data updated 14 Sep 2026; prices through 1 Sep 2026).
-
Bioceres Crop Solutions Corp., Form 20-F for FY2021, FY2022, FY2023, FY2025 (SEC EDGAR); BIOX 4Q25 consolidated financial statements.
-
Mercado Argentino de Valores — Fideicomiso Financiero Insuagro VI, VII, VIII, IX, XII prospectuses, subscription notices and presentations; Bolsa de Comercio de Rosario — Insuagro X prospectus supplement (Dec 2022).
-
InsuAgro corporate website (insuagro.com.ar), retrieved Oct 2026.
-
MarketScreener/Zonebourse (results calendar, going-concern headline, valuation); Fintel; TradingView; Simply Wall St; iocharts; Twelve Data; FinancialFilings.com.
-
Press: iProfesional (Apr 2021; Dec 2025–Jul 2026), El Economista (Mar 2026), Canal 26 (Mar 2026), Bichos de Campo (2025–2026), El Cronista (2025–2026), Forbes Argentina (2026), Safras (BIOX Q1 FY2026), Infocampo, Agrofy News, Mercado, AgroLatam, De Frente al Campo (CASAFE and INTA market data).
Unlock Company Financials
Unlock this company profile to view its financial data.
View Subscription PlansExecutive Leadership
Executive Leadership Team
| Name | Title | Prior roles | Education |
|---|---|---|---|
Luis S. Delcassé | Chairman, Chief Executive Officer and Managing Director | Not publicly disclosed (Twelve Data also lists him as CEO) | — |
Darío Severi | Administration and Finance Manager | — | — |
Ing. Hermann Welz | Sales Manager | — | Agronomist/engineer title indicated |
Ing. Rodolfo Vicetto | Marketing and Production Manager | — | Engineer title indicated |
Ing. José Mrejen | Commercial Director and Director | — | Engineer title indicated |
“—” = not publicly disclosed.
Governance Overview
| Item | Detail | Source |
|---|---|---|
Board size | Three directors at April 2021 closing (two replaced by Bioceres nominees) | BIOX 20-F FY2022 |
Committees | Statutory Comisión Fiscalizadora (supervisory committee) exists; audit committee status not publicly disclosed (CNV rules generally require an audit committee for listed companies; but small issuers may qualify for exemptions) | FinancialFilings.com (Comisión Fiscalizadora report) |
Chair/CEO separation | Data provider shows combined Chairman/CEO role | StockAnalysis/EODHD |
Dual-class structure | Class A shares: 5 votes; Class B (listed): 1 vote | BIOX 20-F FY2025 |
Major Shareholders
| Holder | Shares | % equity | % votes | Source |
|---|---|---|---|---|
Bioceres Crop Solutions Corp. (Nasdaq: BIOX) | 13,489,990 | 61.32 | 61.22 | BIOX 20-F FY2023 |
Public free float | ~6.2M (est. from 28.2% float) | ~28.2 | — | MarketScreener |
Other holders (residual, likely legacy founders/insiders) | ~2.3M (residual, analyst-derived) | ~10.5 | — | Analyst derivation |
“—” = not publicly disclosed.
Competitive Landscape
Key Competitors
| Competitor | Type | Overlap with InsuAgro | Relative positioning |
|---|---|---|---|
Rizobacter Argentina S.A. (sister, BIOX) | Domestic formulator; adjuvants, inoculants, biologicals | Adjuvants, seed treatments, nutrition | Larger, industrial capacity, group flagship; overlapping channel |
Syngenta (ChemChina/Sinochem) | Multinational R&D | Herbicides, fungicides, seed treatments | Premium brands, broad portfolio |
Bayer Crop Science | Multinational R&D | Herbicides, fungicides, insecticides | Premium brands, traits integration |
Corteva Agriscience | Multinational R&D | Herbicides, insecticides | Premium brands, seeds |
BASF Agricultural Solutions | Multinational R&D | Fungicides, herbicides | Premium fungicides |
FMC | Multinational (also a disclosed InsuAgro supplier) | Insecticides, herbicides | Supplier-competitor |
UPL / UPL Argentina | Global generic | Broad generic portfolio | Scale generic, aggressive pricing |
ADAMA | Global generic | Broad generic portfolio | Scale generic |
Nufarm | Global generic | Herbicides | Generic herbicides |
Albaugh (incl. Atanor in Argentina) | Global generic with local manufacturing | Herbicides (glyphosate, 2,4-D) | Local production advantage |
Red Surcos | Domestic formulator/distributor | Generic portfolio | Direct domestic peer |
Gleba | Domestic formulator | Generic portfolio | Direct domestic peer |
Chemotécnica | Domestic formulator | Generic portfolio | Direct domestic peer |
Agrofina | Domestic formulator | Generic portfolio | Direct domestic peer |
Summit Agro (Sumitomo) | Distributor | Specialty/generic | Japanese-backed distributor |
Peer Comparison FY2026
| Metric | InsuAgro (FY2026, ARS) | Bioceres Crop Solutions (parent, US$) | Rizobacter |
|---|---|---|---|
Revenue | ARS 41,059M | — | — |
Revenue growth | −5.2% nominal | −17% (Q1 FY2026) | — |
Gross margin | 23.3% | 47% (Q1 FY2026) | — |
Operating margin | −0.8% | — | — |
Leverage | Net debt ARS 25.4bn; D/E 4.5x | Financial debt US$228.8M (Mar 2026); equity US$64.1M (FY end) | Restructured ~US$42M ONs (May 2026) |
Recent Developments
Contract wins, product launches, layoffs/hiring and regulatory actions specific to InsuAgro: not publicly disclosed in the period.



